van Nispen Ruth Ma, Virgili Gianni, Hoeben Mirke, Langelaan Maaike, Klevering Jeroen, Keunen Jan Ee, van Rens Ger Hmb
Amsterdam University Medical Centers, Vrije Universiteit, Department of Ophthalmology, Amsterdam Public Health research institute, Amsterdam, Netherlands.
University of Florence, Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA), Largo Palagi, 1, Florence, Italy, 50134.
Cochrane Database Syst Rev. 2020 Jan 27;1(1):CD006543. doi: 10.1002/14651858.CD006543.pub2.
Low vision rehabilitation aims to optimise the use of residual vision after severe vision loss, but also aims to teach skills in order to improve visual functioning in daily life. Other aims include helping people to adapt to permanent vision loss and improving psychosocial functioning. These skills promote independence and active participation in society. Low vision rehabilitation should ultimately improve quality of life (QOL) for people who have visual impairment.
To assess the effectiveness of low vision rehabilitation interventions on health-related QOL (HRQOL), vision-related QOL (VRQOL) or visual functioning and other closely related patient-reported outcomes in visually impaired adults.
We searched relevant electronic databases and trials registers up to 18 September 2019.
We included randomised controlled trials (RCTs) investigating HRQOL, VRQOL and related outcomes of adults, with an irreversible visual impairment (World Health Organization criteria). We included studies that compared rehabilitation interventions with active or inactive control.
We used standard methods expected by Cochrane. We assessed the certainty of the evidence using the GRADE approach.
We included 44 studies (73 reports) conducted in North America, Australia, Europe and Asia. Considering the clinical diversity of low vision rehabilitation interventions, the studies were categorised into four groups of related intervention types (and by comparator): (1) psychological therapies and/or group programmes, (2) methods of enhancing vision, (3) multidisciplinary rehabilitation programmes, (4) other programmes. Comparators were no care or waiting list as an inactive control group, usual care or other active control group. Participants included in the reported studies were mainly older adults with visual impairment or blindness, often as a result of age-related macular degeneration (AMD). Study settings were often hospitals or low vision rehabilitation services. Effects were measured at the short-term (six months or less) in most studies. Not all studies reported on funding, but those who did were supported by public or non-profit funders (N = 31), except for two studies. Compared to inactive comparators, we found very low-certainty evidence of no beneficial effects on HRQOL that was imprecisely estimated for psychological therapies and/or group programmes (SMD 0.26, 95% CI -0.28 to 0.80; participants = 183; studies = 1) and an imprecise estimate suggesting little or no effect of multidisciplinary rehabilitation programmes (SMD -0.08, 95% CI -0.37 to 0.21; participants = 183; studies = 2; I = 0%); no data were available for methods of enhancing vision or other programmes. Regarding VRQOL, we found low- or very low-certainty evidence of imprecisely estimated benefit with psychological therapies and/or group programmes (SMD -0.23, 95% CI -0.53 to 0.08; studies = 2; I = 24%) and methods of enhancing vision (SMD -0.19, 95% CI -0.54 to 0.15; participants = 262; studies = 5; I = 34%). Two studies using multidisciplinary rehabilitation programmes showed beneficial but inconsistent results, of which one study, which was at low risk of bias and used intensive rehabilitation, recorded a very large and significant effect (SMD: -1.64, 95% CI -2.05 to -1.24), and the other a small and uncertain effect (SMD -0.42, 95%: -0.90 to 0.07). Compared to active comparators, we found very low-certainty evidence of small or no beneficial effects on HRQOL that were imprecisely estimated with psychological therapies and/or group programmes including no difference (SMD -0.09, 95% CI -0.39 to 0.20; participants = 600; studies = 4; I = 67%). We also found very low-certainty evidence of small or no beneficial effects with methods of enhancing vision, that were imprecisely estimated (SMD -0.09, 95% CI -0.28 to 0.09; participants = 443; studies = 2; I = 0%) and multidisciplinary rehabilitation programmes (SMD -0.10, 95% CI -0.31 to 0.12; participants = 375; studies = 2; I = 0%). Concerning VRQOL, low-certainty evidence of small or no beneficial effects that were imprecisely estimated, was found with psychological therapies and/or group programmes (SMD -0.11, 95% CI -0.24 to 0.01; participants = 1245; studies = 7; I = 19%) and moderate-certainty evidence of small effects with methods of enhancing vision (SMD -0.24, 95% CI -0.40 to -0.08; participants = 660; studies = 7; I = 16%). No additional benefit was found with multidisciplinary rehabilitation programmes (SMD 0.01, 95% CI -0.18 to 0.20; participants = 464; studies = 3; I = 0%; low-certainty evidence). Among secondary outcomes, very low-certainty evidence of a significant and large, but imprecisely estimated benefit on self-efficacy or self-esteem was found for psychological therapies and/or group programmes versus waiting list or no care (SMD -0.85, 95% CI -1.48 to -0.22; participants = 456; studies = 5; I = 91%). In addition, very low-certainty evidence of a significant and large estimated benefit on depression was found for psychological therapies and/or group programmes versus waiting list or no care (SMD -1.23, 95% CI -2.18 to -0.28; participants = 456; studies = 5; I = 94%), and moderate-certainty evidence of a small benefit versus usual care (SMD -0.14, 95% CI -0.25 to -0.04; participants = 1334; studies = 9; I = 0%). ln the few studies in which (serious) adverse events were reported, these seemed unrelated to low vision rehabilitation.
AUTHORS' CONCLUSIONS: In this Cochrane Review, no evidence of benefit was found of diverse types of low vision rehabilitation interventions on HRQOL. We found low- and moderate-certainty evidence, respectively, of a small benefit on VRQOL in studies comparing psychological therapies or methods for enhancing vision with active comparators. The type of rehabilitation varied among studies, even within intervention groups, but benefits were detected even if compared to active control groups. Studies were conducted on adults with visual impairment mainly of older age, living in high-income countries and often having AMD. Most of the included studies on low vision rehabilitation had a short follow-up, Despite these limitations, the consistent direction of the effects in this review towards benefit justifies further research activities of better methodological quality including longer maintenance effects and costs of several types of low vision rehabilitation. Research on the working mechanisms of components of rehabilitation interventions in different settings, including low-income countries, is also needed.
低视力康复旨在优化严重视力丧失后残余视力的使用,同时旨在教授技能以改善日常生活中的视觉功能。其他目标包括帮助人们适应永久性视力丧失并改善心理社会功能。这些技能可促进独立性并积极参与社会。低视力康复最终应改善视力障碍者的生活质量(QOL)。
评估低视力康复干预措施对视力受损成年人的健康相关生活质量(HRQOL)、视力相关生活质量(VRQOL)或视觉功能以及其他密切相关的患者报告结局的有效性。
我们检索了截至2019年9月18日的相关电子数据库和试验注册库。
我们纳入了调查成年人HRQOL、VRQOL及相关结局的随机对照试验(RCT),这些成年人患有不可逆性视力障碍(世界卫生组织标准)。我们纳入了将康复干预措施与积极或非积极对照进行比较的研究。
我们采用了Cochrane期望的标准方法。我们使用GRADE方法评估证据的确定性。
我们纳入了在北美、澳大利亚、欧洲和亚洲进行的44项研究(73份报告)。考虑到低视力康复干预措施的临床多样性,这些研究被分为四组相关的干预类型(并按对照进行分类):(1)心理治疗和/或团体项目,(2)增强视力的方法,(3)多学科康复项目,(4)其他项目。对照为无治疗或等待名单作为非积极对照组、常规治疗或其他积极对照组。纳入报告研究的参与者主要是患有视力障碍或失明的老年人,通常是由于年龄相关性黄斑变性(AMD)所致。研究场所通常是医院或低视力康复服务机构。大多数研究在短期(六个月或更短时间)内测量效果。并非所有研究都报告了资金来源,但除两项研究外,那些报告了资金来源的研究得到了公共或非营利性资助者的支持(N = 31)。与非积极对照相比,我们发现心理治疗和/或团体项目对HRQOL无有益影响的证据确定性非常低且估计不精确(标准化均数差[SMD] 0.26,95%置信区间[CI] -0.28至0.80;参与者 = 183;研究 = 1),多学科康复项目的估计不精确,表明几乎没有影响(SMD -0.08,95% CI -0.37至0.21;参与者 = 183;研究 = 2;I² = 0%);增强视力的方法或其他项目没有可用数据。关于VRQOL,我们发现心理治疗和/或团体项目(SMD -0.23,95% CI -0.53至0.08;研究 = 2;I² = 24%)和增强视力的方法(SMD -0.19,95% CI -0.54至0.15;参与者 = 262;研究 = 5;I² = 34%)对VRQOL有益但估计不精确的证据确定性低或非常低。两项使用多学科康复项目的研究显示出有益但不一致的结果,其中一项研究偏倚风险低且采用强化康复,记录了非常大且显著的效果(SMD:-1.64,95% CI -2.05至-1.24),另一项研究效果小且不确定(SMD -0.42,95% CI:-0.90至0.07)。与积极对照相比,我们发现心理治疗和/或团体项目对HRQOL有小的或无有益影响的证据确定性非常低且估计不精确,包括无差异(SMD -0.09,95% CI -0.39至0.20;参与者 = 600;研究 = 4;I² = 67%)。我们还发现增强视力的方法有小的或无有益影响的证据确定性非常低且估计不精确(SMD -0.09,95% CI -0.28至0.09;参与者 = 443;研究 = 2;I² = 0%)以及多学科康复项目(SMD -0.10,95% CI -0.31至0.12;参与者 = 375;研究 = 2;I² = 0%)。关于VRQOL,心理治疗和/或团体项目有小的或无有益影响且估计不精确的证据确定性低(SMD -0.11,95% CI -0.24至0.01;参与者 = 1245;研究 = 7;I² = 19%),增强视力的方法有小的有益影响的证据确定性中等(SMD -0.24,95% CI -0.40至-0.08;参与者 = 660;研究 = 7;I² = 16%)。多学科康复项目未发现额外益处(SMD 0.01,95% CI -0.18至0.20;参与者 = 464;研究 = 3;I² = 0%;证据确定性低)。在少数报告了(严重)不良事件的研究中,这些事件似乎与低视力康复无关。
在本Cochrane系统评价中,未发现多种类型的低视力康复干预措施对HRQOL有有益证据。在将心理治疗或增强视力的方法与积极对照进行比较的研究中,我们分别发现对VRQOL有小的有益影响的证据确定性低和中等。研究中的康复类型各不相同,即使在干预组内也是如此,但即使与积极对照组相比也检测到了益处。研究针对的主要是年龄较大、生活在高收入国家且常患有AMD的视力受损成年人。大多数纳入的低视力康复研究随访时间较短。尽管有这些局限性,但本系统评价中效果的一致有益方向证明有必要开展方法学质量更高的进一步研究活动,包括更长时间的维持效果和几种低视力康复类型的成本。还需要对不同环境(包括低收入国家)中康复干预措施组成部分的作用机制进行研究。